Biotech IPO momentum returned in April as four newly public companies raised a combined $1.5 billion, the biggest month in five years, according to IPO research firm Renaissance Capital. The reported issuers include Hemab Therapeutics and Seaport Therapeutics, each described as upsized IPOs. For the biotech sector, the uptick signals improved investor appetite for early-stage and platform-driven stories—particularly when underwriting supports higher gross proceeds. It also provides more public-market benchmarks for pricing and risk tolerance across therapeutic modalities. Individual deal structures and use of proceeds weren’t detailed in the excerpt, but the common theme is that the market rewarded new issuers with substantial capital inflows. Capital-market access can accelerate timeline to first readouts, strengthen balance sheets for R&D, and raise the probability of near-term partnerships.